speb/financial-data huggingface dataset:
SICAGEN.NS income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 1779800000.00
SICAGEN.NS income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 23900000.00
SICAGEN.NS income_statement (quarterly, 2025-06-30) — Special Income Charges: 0.00
SICAGEN.NS income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 0.00
SICAGEN.NS income_statement (quarterly, 2025-06-30) — Tax Provision: 16900000.00
SICAGEN.NS income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.27
SICAGEN.NS income_statement (quarterly, 2025-06-30) — Total Expenses: 1971900000.00
SICAGEN.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items: 0.00
SICAGEN.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: 0.00
SICAGEN.NS income_statement (quarterly, 2025-09-30) — +Operating Expense: 219000000.00
SICAGEN.NS income_statement (quarterly, 2025-09-30) — +Total Revenue: 2267600000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 613900000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 2603300000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Assets Held For Sale Current: 8400000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Available For Sale Securities: 960300000.00
SICAGEN.NS income_statement (quarterly, 2025-09-30) — Basic Average Shares: 39807692.00
SICAGEN.NS income_statement (quarterly, 2025-09-30) — Basic EPS: 1.04
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Capital Lease Obligations: 172400000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Capital Stock: 395700000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 18500000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 1376300000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Common Stock: 395700000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 5179900000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Construction In Progress: 6000000.00
SICAGEN.NS income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 1981700000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Current Assets: 5933000000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Current Capital Lease Obligation: 25500000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Current Debt: 1467700000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 1493200000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 2909500000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Current Provisions: 8900000.00
SICAGEN.NS income_statement (quarterly, 2025-09-30) — Depreciation And Amortization In Income Statement: 23700000.00
SICAGEN.NS income_statement (quarterly, 2025-09-30) — Depreciation Income Statement: 23700000.00
SICAGEN.NS income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 39807692.00
SICAGEN.NS income_statement (quarterly, 2025-09-30) — Diluted EPS: 1.04
SICAGEN.NS income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: 41400000.00
SICAGEN.NS income_statement (quarterly, 2025-09-30) — EBIT: 84400000.00
SICAGEN.NS income_statement (quarterly, 2025-09-30) — EBITDA: 108100000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 1600000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Gross PPE: 1364100000.00
SICAGEN.NS income_statement (quarterly, 2025-09-30) — Gross Profit: 285900000.00
SICAGEN.NS income_statement (quarterly, 2025-09-30) — Interest Expense: 27100000.00
SICAGEN.NS income_statement (quarterly, 2025-09-30) — Interest Expense Non Operating: 27100000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Inventory: 1471700000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Invested Capital: 6647600000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Investment Properties: 42200000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Investmentin Financial Assets: 960300000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Long Term Capital Lease Obligation: 146900000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 146900000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Long Term Provisions: 4800000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Net Debt: 1449200000.00
SICAGEN.NS income_statement (quarterly, 2025-09-30) — Net Income: 41400000.00
SICAGEN.NS income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: 41400000.00
SICAGEN.NS income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: 41400000.00
SICAGEN.NS income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: 41400000.00
SICAGEN.NS income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: 41400000.00
SICAGEN.NS income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: 41400000.00
SICAGEN.NS income_statement (quarterly, 2025-09-30) — Net Interest Income: -27100000.00
SICAGEN.NS income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: -27100000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Net PPE: 1364100000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 5178300000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Liabilities: 59200000.00
SICAGEN.NS income_statement (quarterly, 2025-09-30) — Normalized EBITDA: 108100000.00
SICAGEN.NS income_statement (quarterly, 2025-09-30) — Normalized Income: 41400000.00
SICAGEN.NS income_statement (quarterly, 2025-09-30) — Operating Income: 66900000.00
SICAGEN.NS income_statement (quarterly, 2025-09-30) — Operating Revenue: 2267600000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 39571684.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Other Current Assets: 233500000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Other Current Liabilities: 52300000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Other Equity Interest: 4784200000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Other Intangible Assets: 1600000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Other Non Current Assets: 1900000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Other Non Current Liabilities: 2700000.00
SICAGEN.NS income_statement (quarterly, 2025-09-30) — Other Non Operating Income Expenses: 17500000.00
SICAGEN.NS income_statement (quarterly, 2025-09-30) — Other Operating Expenses: 117700000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Other Properties: 1358100000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Other Receivables: 200000000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Other Short Term Investments: 1357800000.00
SICAGEN.NS income_statement (quarterly, 2025-09-30) — Otherunder Preferred Stock Dividend: 0.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Payables: 634100000.00
SICAGEN.NS income_statement (quarterly, 2025-09-30) — Pretax Income: 57300000.00
SICAGEN.NS income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 1981700000.00
SICAGEN.NS income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 23700000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Share Issued: 39571684.00
SICAGEN.NS income_statement (quarterly, 2025-09-30) — Special Income Charges: 0.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 5179900000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 5178300000.00
SICAGEN.NS income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: 0.00
SICAGEN.NS income_statement (quarterly, 2025-09-30) — Tax Provision: 15900000.00
SICAGEN.NS income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.28
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Taxes Receivable: 39800000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Total Assets: 8303100000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 5179900000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Total Debt: 1640100000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 5179900000.00
SICAGEN.NS income_statement (quarterly, 2025-09-30) — Total Expenses: 2200700000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 3123200000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 2370100000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 213700000.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Total Tax Payable: 20200000.00
SICAGEN.NS income_statement (quarterly, 2025-09-30) — Total Unusual Items: 0.00
SICAGEN.NS income_statement (quarterly, 2025-09-30) — Total Unusual Items Excluding Goodwill: 0.00
SICAGEN.NS balance_sheet (quarterly, 2025-09-30) — Working Capital: 3023500000.00
SICAGEN.NS income_statement (quarterly, 2025-12-31) — +Operating Expense: 196300000.00
SICAGEN.NS income_statement (quarterly, 2025-12-31) — +Total Revenue: 2642700000.00
SICAGEN.NS income_statement (quarterly, 2025-12-31) — Basic Average Shares: 39440000.00
SICAGEN.NS income_statement (quarterly, 2025-12-31) — Basic EPS: 1.25
SICAGEN.NS income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 2377400000.00
SICAGEN.NS income_statement (quarterly, 2025-12-31) — Depreciation And Amortization In Income Statement: 23700000.00
SICAGEN.NS income_statement (quarterly, 2025-12-31) — Depreciation Income Statement: 23700000.00
SICAGEN.NS income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 39440000.00
SICAGEN.NS income_statement (quarterly, 2025-12-31) — Diluted EPS: 1.25
SICAGEN.NS income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: 49300000.00
SICAGEN.NS income_statement (quarterly, 2025-12-31) — EBIT: 95900000.00
SICAGEN.NS income_statement (quarterly, 2025-12-31) — EBITDA: 119600000.00
SICAGEN.NS income_statement (quarterly, 2025-12-31) — Gross Profit: 265300000.00
SICAGEN.NS income_statement (quarterly, 2025-12-31) — Interest Expense: 26800000.00
SICAGEN.NS income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 26800000.00
SICAGEN.NS income_statement (quarterly, 2025-12-31) — Net Income: 49300000.00
SICAGEN.NS income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: 49300000.00
SICAGEN.NS income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: 49300000.00
SICAGEN.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 49300000.00
SICAGEN.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 49300000.00
SICAGEN.NS income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: 49300000.00
SICAGEN.NS income_statement (quarterly, 2025-12-31) — Net Interest Income: -26800000.00
SICAGEN.NS income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: -26800000.00
SICAGEN.NS income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 122700000.00
SICAGEN.NS income_statement (quarterly, 2025-12-31) — Normalized Income: 51511722.14
SICAGEN.NS income_statement (quarterly, 2025-12-31) — Operating Income: 69000000.00
SICAGEN.NS income_statement (quarterly, 2025-12-31) — Operating Revenue: 2642700000.00
SICAGEN.NS income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: 30000000.00
SICAGEN.NS income_statement (quarterly, 2025-12-31) — Other Operating Expenses: 91100000.00
SICAGEN.NS income_statement (quarterly, 2025-12-31) — Other Special Charges: 3100000.00
SICAGEN.NS income_statement (quarterly, 2025-12-31) — Otherunder Preferred Stock Dividend: 0.00
SICAGEN.NS income_statement (quarterly, 2025-12-31) — Pretax Income: 69100000.00
SICAGEN.NS income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 2377400000.00
SICAGEN.NS income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 23700000.00
SICAGEN.NS income_statement (quarterly, 2025-12-31) — Special Income Charges: -3100000.00
SICAGEN.NS income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: -888277.86
SICAGEN.NS income_statement (quarterly, 2025-12-31) — Tax Provision: 19800000.00
SICAGEN.NS income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.29
SICAGEN.NS income_statement (quarterly, 2025-12-31) — Total Expenses: 2573700000.00
SICAGEN.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items: -3100000.00
SICAGEN.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: -3100000.00
SICAGEN.NS income_statement (annual, 2026-03-31) — +Operating Expense: 843100000.00
SICAGEN.NS income_statement (quarterly, 2026-03-31) — +Operating Expense: 235700000.00
SICAGEN.NS income_statement (annual, 2026-03-31) — +Total Revenue: 9734800000.00
SICAGEN.NS income_statement (quarterly, 2026-03-31) — +Total Revenue: 2779100000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Accounts Payable: 572600000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 572600000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Accounts Receivable: 2435700000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 2435700000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Assets Held For Sale Current: 15800000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Assets Held For Sale Current: 15800000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Available For Sale Securities: 692400000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Available For Sale Securities: 692400000.00
SICAGEN.NS income_statement (quarterly, 2026-03-31) — Basic Average Shares: 39469027.00
SICAGEN.NS income_statement (quarterly, 2026-03-31) — Basic EPS: 1.13
SICAGEN.NS cash_flow (annual, 2026-03-31) — Beginning Cash Position: 67600000.00
SICAGEN.NS cash_flow (annual, 2026-03-31) — Capital Expenditure: -63700000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Capital Lease Obligations: 159100000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 159100000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Capital Stock: 395700000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Capital Stock: 395700000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Cash And Cash Equivalents: 249700000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 249700000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 916200000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 916200000.00
SICAGEN.NS cash_flow (annual, 2026-03-31) — Cash Dividends Paid: -39600000.00
SICAGEN.NS cash_flow (annual, 2026-03-31) — Change In Inventory: -187200000.00
SICAGEN.NS cash_flow (annual, 2026-03-31) — Change In Other Current Assets: -54700000.00
SICAGEN.NS cash_flow (annual, 2026-03-31) — Change In Payable: 327900000.00
SICAGEN.NS cash_flow (annual, 2026-03-31) — Change In Receivables: -218600000.00
SICAGEN.NS cash_flow (annual, 2026-03-31) — Change In Working Capital: -132600000.00
SICAGEN.NS cash_flow (annual, 2026-03-31) — Changes In Cash: 182100000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Common Stock: 395700000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Common Stock: 395700000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Common Stock Equity: 4950100000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 4950100000.00
SICAGEN.NS income_statement (annual, 2026-03-31) — Cost Of Revenue: 8606700000.00
SICAGEN.NS income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 2467800000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Current Assets: 5297700000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Current Assets: 5297700000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Current Capital Lease Obligation: 32200000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 32200000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Current Debt: 1431100000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Current Debt: 1431100000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Current Debt And Capital Lease Obligation: 1463300000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 1463300000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Current Liabilities: 2247000000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 2247000000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Current Provisions: 17700000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Current Provisions: 17700000.00
SICAGEN.NS cash_flow (annual, 2026-03-31) — Depreciation: 108000000.00
SICAGEN.NS cash_flow (annual, 2026-03-31) — Depreciation And Amortization: 108000000.00
SICAGEN.NS income_statement (annual, 2026-03-31) — Depreciation And Amortization In Income Statement: 108000000.00
SICAGEN.NS income_statement (quarterly, 2026-03-31) — Depreciation And Amortization In Income Statement: 36700000.00
SICAGEN.NS income_statement (annual, 2026-03-31) — Depreciation Income Statement: 108000000.00
SICAGEN.NS income_statement (quarterly, 2026-03-31) — Depreciation Income Statement: 36700000.00
SICAGEN.NS income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 39469027.00
SICAGEN.NS income_statement (quarterly, 2026-03-31) — Diluted EPS: 1.13
SICAGEN.NS income_statement (annual, 2026-03-31) — Diluted NI Availto Com Stockholders: 180700000.00
SICAGEN.NS income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: 44600000.00
SICAGEN.NS cash_flow (annual, 2026-03-31) — Dividends Received Cfi: 12900000.00
SICAGEN.NS income_statement (annual, 2026-03-31) — EBIT: 379700000.00
SICAGEN.NS income_statement (quarterly, 2026-03-31) — EBIT: 106700000.00
SICAGEN.NS income_statement (annual, 2026-03-31) — EBITDA: 487700000.00
SICAGEN.NS income_statement (quarterly, 2026-03-31) — EBITDA: 143400000.00
SICAGEN.NS cash_flow (annual, 2026-03-31) — End Cash Position: 249700000.00
SICAGEN.NS cash_flow (annual, 2026-03-31) — Financing Cash Flow: -190200000.00
SICAGEN.NS cash_flow (annual, 2026-03-31) — Free Cash Flow: 378100000.00
SICAGEN.NS cash_flow (annual, 2026-03-31) — Gain Loss On Investment Securities: -12900000.00
SICAGEN.NS cash_flow (annual, 2026-03-31) — Gain Loss On Sale Of PPE: 4800000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Goodwill And Other Intangible Assets: 1400000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 1400000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Gross PPE: 1370000000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Gross PPE: 1370000000.00
SICAGEN.NS income_statement (annual, 2026-03-31) — Gross Profit: 1128100000.00
SICAGEN.NS income_statement (quarterly, 2026-03-31) — Gross Profit: 311300000.00
SICAGEN.NS income_statement (annual, 2026-03-31) — Interest Expense: 127200000.00
SICAGEN.NS income_statement (quarterly, 2026-03-31) — Interest Expense: 42900000.00
SICAGEN.NS income_statement (annual, 2026-03-31) — Interest Expense Non Operating: 127200000.00
SICAGEN.NS income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 42900000.00
SICAGEN.NS cash_flow (annual, 2026-03-31) — Interest Paid Cff: -104500000.00
SICAGEN.NS cash_flow (annual, 2026-03-31) — Interest Received Cfi: 58500000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Inventory: 1482000000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Inventory: 1482000000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Invested Capital: 6381200000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Invested Capital: 6381200000.00
SICAGEN.NS cash_flow (annual, 2026-03-31) — Investing Cash Flow: -69500000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Investment Properties: 31900000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Investment Properties: 31900000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Investmentin Financial Assets: 692400000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Investmentin Financial Assets: 692400000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Long Term Capital Lease Obligation: 126900000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 126900000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 126900000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 126900000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Long Term Provisions: 5800000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Long Term Provisions: 5800000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Net Debt: 1181400000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Net Debt: 1181400000.00
SICAGEN.NS cash_flow (annual, 2026-03-31) — Net Foreign Currency Exchange Gain Loss: 146300000.00
SICAGEN.NS income_statement (annual, 2026-03-31) — Net Income: 180700000.00
SICAGEN.NS income_statement (quarterly, 2026-03-31) — Net Income: 44600000.00
SICAGEN.NS income_statement (annual, 2026-03-31) — Net Income Common Stockholders: 180700000.00
SICAGEN.NS income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: 44600000.00
SICAGEN.NS income_statement (annual, 2026-03-31) — Net Income Continuous Operations: 180700000.00
SICAGEN.NS income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: 44600000.00
SICAGEN.NS income_statement (annual, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 180700000.00
SICAGEN.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 44600000.00
SICAGEN.NS income_statement (annual, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 180700000.00
SICAGEN.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 44600000.00
SICAGEN.NS cash_flow (annual, 2026-03-31) — Net Income From Continuing Operations: 255600000.00
SICAGEN.NS income_statement (annual, 2026-03-31) — Net Income Including Noncontrolling Interests: 180700000.00
SICAGEN.NS income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: 44600000.00
SICAGEN.NS income_statement (annual, 2026-03-31) — Net Interest Income: -127200000.00
SICAGEN.NS income_statement (quarterly, 2026-03-31) — Net Interest Income: -42900000.00
SICAGEN.NS cash_flow (annual, 2026-03-31) — Net Investment Purchase And Sale: -81100000.00
SICAGEN.NS income_statement (annual, 2026-03-31) — Net Non Operating Interest Income Expense: -127200000.00
SICAGEN.NS income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: -42900000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Net PPE: 1370000000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Net PPE: 1370000000.00
SICAGEN.NS cash_flow (annual, 2026-03-31) — Net PPE Purchase And Sale: -59800000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Net Tangible Assets: 4948700000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 4948700000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Taxes Liabilities: 62700000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Liabilities: 62700000.00
SICAGEN.NS income_statement (annual, 2026-03-31) — Normalized EBITDA: 490800000.00
SICAGEN.NS income_statement (quarterly, 2026-03-31) — Normalized EBITDA: 143400000.00
SICAGEN.NS income_statement (annual, 2026-03-31) — Normalized Income: 182918495.05
SICAGEN.NS income_statement (quarterly, 2026-03-31) — Normalized Income: 44600000.00
SICAGEN.NS cash_flow (annual, 2026-03-31) — Operating Cash Flow: 441800000.00
SICAGEN.NS income_statement (annual, 2026-03-31) — Operating Income: 285000000.00
SICAGEN.NS income_statement (quarterly, 2026-03-31) — Operating Income: 75600000.00
SICAGEN.NS income_statement (annual, 2026-03-31) — Operating Revenue: 9734800000.00
SICAGEN.NS income_statement (quarterly, 2026-03-31) — Operating Revenue: 2779100000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Ordinary Shares Number: 39571684.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 39571684.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Other Current Assets: 227600000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Other Current Assets: 227600000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Other Current Liabilities: 93600000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Other Current Liabilities: 93600000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Other Equity Interest: 4554400000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Other Equity Interest: 4554400000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Other Intangible Assets: 1400000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Other Intangible Assets: 1400000.00
SICAGEN.NS cash_flow (annual, 2026-03-31) — Other Non Cash Items: 45000000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Other Non Current Assets: 1900000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: 1900000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Other Non Current Liabilities: 2700000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Other Non Current Liabilities: 2700000.00
SICAGEN.NS income_statement (annual, 2026-03-31) — Other Non Operating Income Expenses: 97800000.00
SICAGEN.NS income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: 31100000.00
SICAGEN.NS income_statement (annual, 2026-03-31) — Other Operating Expenses: 425300000.00
SICAGEN.NS income_statement (quarterly, 2026-03-31) — Other Operating Expenses: 120600000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Other Properties: 1370000000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Other Properties: 1370000000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Other Receivables: 175000000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Other Receivables: 175000000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Other Short Term Investments: 666500000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 666500000.00
SICAGEN.NS income_statement (annual, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
SICAGEN.NS income_statement (quarterly, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Payables: 597700000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Payables: 597700000.00
SICAGEN.NS income_statement (annual, 2026-03-31) — Pretax Income: 252500000.00
SICAGEN.NS income_statement (quarterly, 2026-03-31) — Pretax Income: 63800000.00
SICAGEN.NS cash_flow (annual, 2026-03-31) — Provisionand Write Offof Assets: 68600000.00
SICAGEN.NS cash_flow (annual, 2026-03-31) — Purchase Of Investment: -98400000.00
SICAGEN.NS cash_flow (annual, 2026-03-31) — Purchase Of PPE: -63700000.00
SICAGEN.NS income_statement (annual, 2026-03-31) — Reconciled Cost Of Revenue: 8606700000.00
SICAGEN.NS income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 2467800000.00
SICAGEN.NS income_statement (annual, 2026-03-31) — Reconciled Depreciation: 108000000.00
SICAGEN.NS income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 36700000.00
SICAGEN.NS cash_flow (annual, 2026-03-31) — Sale Of Investment: 17300000.00
SICAGEN.NS cash_flow (annual, 2026-03-31) — Sale Of PPE: 3900000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Share Issued: 39571684.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Share Issued: 39571684.00
SICAGEN.NS income_statement (annual, 2026-03-31) — Special Income Charges: -3100000.00
SICAGEN.NS income_statement (quarterly, 2026-03-31) — Special Income Charges: 0.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Stockholders Equity: 4950100000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 4950100000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Tangible Book Value: 4948700000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 4948700000.00
SICAGEN.NS income_statement (annual, 2026-03-31) — Tax Effect Of Unusual Items: -881504.95
SICAGEN.NS income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
SICAGEN.NS income_statement (annual, 2026-03-31) — Tax Provision: 71800000.00
SICAGEN.NS income_statement (quarterly, 2026-03-31) — Tax Provision: 19200000.00
SICAGEN.NS income_statement (annual, 2026-03-31) — Tax Rate For Calcs: 0.28
SICAGEN.NS income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.30
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Taxes Receivable: 45400000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Taxes Receivable: 45400000.00
SICAGEN.NS cash_flow (annual, 2026-03-31) — Taxes Refund Paid: -41000000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Total Assets: 7395300000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Total Assets: 7395300000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Total Capitalization: 4950100000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 4950100000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Total Debt: 1590200000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Total Debt: 1590200000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Total Equity Gross Minority Interest: 4950100000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 4950100000.00
SICAGEN.NS income_statement (annual, 2026-03-31) — Total Expenses: 9449800000.00
SICAGEN.NS income_statement (quarterly, 2026-03-31) — Total Expenses: 2703500000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Total Liabilities Net Minority Interest: 2445200000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 2445200000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Total Non Current Assets: 2097600000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 2097600000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 198200000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 198200000.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Total Tax Payable: 25100000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Total Tax Payable: 25100000.00
SICAGEN.NS income_statement (annual, 2026-03-31) — Total Unusual Items: -3100000.00
SICAGEN.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items: 0.00
SICAGEN.NS income_statement (annual, 2026-03-31) — Total Unusual Items Excluding Goodwill: -3100000.00
SICAGEN.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: 0.00
SICAGEN.NS balance_sheet (annual, 2026-03-31) — Working Capital: 3050700000.00
SICAGEN.NS balance_sheet (quarterly, 2026-03-31) — Working Capital: 3050700000.00
SICO.V income_statement (quarterly, 2024-09-30) — Basic Average Shares: 32616264.00
SICO.V income_statement (quarterly, 2024-09-30) — Basic EPS: -0.02
SICO.V income_statement (quarterly, 2024-09-30) — Depreciation Amortization Depletion Income Statement: 0.00
SICO.V income_statement (quarterly, 2024-09-30) — Depreciation And Amortization In Income Statement: 0.00
SICO.V income_statement (quarterly, 2024-09-30) — Depreciation Income Statement: 0.00
SICO.V income_statement (quarterly, 2024-09-30) — Diluted Average Shares: 32616264.00
SICO.V income_statement (quarterly, 2024-09-30) — Diluted EPS: -0.02
SICO.V income_statement (quarterly, 2024-09-30) — Interest Income: 0.00
SICO.V income_statement (quarterly, 2024-09-30) — Interest Income Non Operating: 0.00
SICO.V income_statement (quarterly, 2024-09-30) — Selling And Marketing Expense: 0.00
SICO.V income_statement (quarterly, 2024-12-31) — +Total Revenue: 0.00
SICO.V cash_flow (quarterly, 2024-12-31) — Changes In Account Receivables: 121347.00
SICO.V income_statement (quarterly, 2024-12-31) — Depreciation Amortization Depletion Income Statement: 68035.00
SICO.V income_statement (quarterly, 2024-12-31) — Depreciation And Amortization In Income Statement: 68035.00
SICO.V income_statement (quarterly, 2024-12-31) — Depreciation Income Statement: 68035.00
SICO.V income_statement (quarterly, 2024-12-31) — Diluted NI Availto Com Stockholders: -4237873.00
SICO.V income_statement (quarterly, 2024-12-31) — EBIT: -4225042.00
SICO.V income_statement (quarterly, 2024-12-31) — General And Administrative Expense: 1335388.00
SICO.V income_statement (quarterly, 2024-12-31) — Interest Expense: 12831.00
SICO.V income_statement (quarterly, 2024-12-31) — Interest Expense Non Operating: 12831.00
SICO.V income_statement (quarterly, 2024-12-31) — Net Income: -4237873.00
SICO.V income_statement (quarterly, 2024-12-31) — Net Income Common Stockholders: -4237873.00
SICO.V income_statement (quarterly, 2024-12-31) — Net Income Continuous Operations: -4237873.00
SICO.V income_statement (quarterly, 2024-12-31) — Net Income From Continuing And Discontinued Operation: -4237873.00
SICO.V income_statement (quarterly, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: -4237873.00
SICO.V income_statement (quarterly, 2024-12-31) — Net Income Including Noncontrolling Interests: -4237873.00
SICO.V income_statement (quarterly, 2024-12-31) — Net Interest Income: -12831.00
SICO.V income_statement (quarterly, 2024-12-31) — Net Non Operating Interest Income Expense: -12831.00
SICO.V cash_flow (quarterly, 2024-12-31) — Net Other Financing Charges: 1330518.00
SICO.V cash_flow (quarterly, 2024-12-31) — Net PPE Purchase And Sale: 0.00
SICO.V income_statement (quarterly, 2024-12-31) — Normalized Income: -4237873.00
SICO.V income_statement (quarterly, 2024-12-31) — Operating Income: -4270195.00
SICO.V income_statement (quarterly, 2024-12-31) — Operating Revenue: 0.00
SICO.V income_statement (quarterly, 2024-12-31) — Other Gand A: 20000.00
SICO.V income_statement (quarterly, 2024-12-31) — Other Operating Expenses: 2866772.00
SICO.V income_statement (quarterly, 2024-12-31) — Pretax Income: -4237873.00
SICO.V cash_flow (quarterly, 2024-12-31) — Purchase Of PPE: 0.00
SICO.V income_statement (quarterly, 2024-12-31) — Reconciled Depreciation: 68035.00
SICO.V income_statement (quarterly, 2024-12-31) — Salaries And Wages: 1315388.00
SICO.V income_statement (quarterly, 2024-12-31) — Selling General And Administration: 1335388.00
SICO.V cash_flow (quarterly, 2024-12-31) — Stock Based Compensation: 1315388.00
SICO.V income_statement (quarterly, 2024-12-31) — Tax Effect Of Unusual Items: 0.00
SICO.V income_statement (quarterly, 2024-12-31) — Tax Rate For Calcs: 0.00
SICO.V income_statement (quarterly, 2024-12-31) — Total Expenses: 4270195.00
SICO.V income_statement (quarterly, 2025-03-31) — +Operating Expense: 727337.00
SICO.V income_statement (quarterly, 2025-03-31) — +Total Revenue: 0.00
SICO.V income_statement (quarterly, 2025-03-31) — Basic Average Shares: 32616264.00